Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager

  • Gómez-Rosel, Marina
  • Rubio-Pérez, Laura
  • Zagorac, Ivana
  • Domínguez-Alonso, Carmen
  • Díez-Alonso, Laura
  • Hangiu, Oana
  • Navarro, Rocío
  • Torres-Ruiz, Raúl
  • Rodriguez-Perales, Sandra
  • Blanco, Francisco J.
  • Compte, Marta
  • Álvarez-Vallina, Luis
  • Blanco, Belén
22 páginas, 5 figuras, Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (Secretion of T cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor efficacy of STAb-T19 cells by blocking the PD-1/PD-L1 axis with conditional 4-1BB costimulation to ensure the long-term persistence of STAb-T cells. Preclinical data show that this combination improves cytotoxic activity and prolongs antileukemic efficacy compared with low-dose single STAb-T therapy. Our findings suggest that the integration of PD-L1 × 4-1BB bsAbs into STAb-T19 therapy may maximize efficacy, thereby opening a promising avenue to address resistance and relapse in B-ALL. Moreover, this approach may pave the way for the development of next-generation cell-based therapies for hematologic and solid malignancies., BB is funded by Fundación Científica de la Asociación Española Contra el Cáncer (INNOV211832BLAN), the Comunidad de Madrid (IND2022/BMD−23732) and the Instituto de Salud Carlos III (ISCIII) (PI20/01030, PI23/01256). LA-V is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021−121711-I00, CPP2022−009762, CPP2022−009765, CPP2023−010827), ISCIII (DTS20/ 00089, PMPTA22/00167), the Asociación Española contra el Cáncer (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS−2021−0090 and FCRIS−2023−0070), the Fundación ‘‘La Caixa’’ (HR21−00761 project IL7R_LungCan), the Comunidad de Madrid (P2022/BMD−7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). M.G.-R. is supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD−23732). FJB is funded by PID2023-152271NB-I00 from MCIN/AEI/10.13039/501100011033. We thank the Proteomics service at CIC bioGUNE and the Molecular Interactions service at CIB-CSIC for assisting with the mass spectrometry and SEC-MALS experiments. This study has adhered to ARRIVE guidelines, Peer reviewed